micro-community-banner
Profile Image
  • Saved
Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary - The Egyptian Heart Journal

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary - The Egyptian Heart Journal

Source : https://tehj.springeropen.com/articles/10.1186/s43044-023-00389-8

Background Hypercholesterolemia is a lipid disorder characterized by excessively high levels of low-density lipoproteins, which encourages fat accumulation in your arteries, hence escalating the chances of heart attack and stroke....

Conclusions: While statin treatments have been extensively researched and are strongly endorsed by randomized controlled trials and clinical guidelines, not every patient can tolerate statin therapy or attain an adequate reduction in LDL-C levels through statin treatment alone. Inclisiran provides convenience as it needs to be administered...

Profile Image
  • Saved
Impact of metformin on statin-associated myopathy risks in dyslipidemia patients - PubMed

Impact of metformin on statin-associated myopathy risks in dyslipidemia patients - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37417539/

A growing number of patients with metabolic disorders are receiving statin and antidiabetic therapies as comedications. A signal of increased risk of myotoxicity due to potential interactions between antidiabetics and...

Conclusions/Relevance: This study found that a comedication with metformin was associated with decreased myopathy risk in statin-treated dyslipidemia patients compared to statin-only users. Our findings suggest that metformin may provide protective effects on potential muscle toxicities induced by statin therapy.

Profile Image
  • Saved
The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction

The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction

Source : https://www.dovepress.com/the-inhibition-of-evolocumab-on-non-infarct-related-artery-disease-in--peer-reviewed-fulltext-article-IJGM

Evolocumab + statin therapy could significantly improve physiological function of coronary arteries, downregulate re-hospitalization rate of STEMI pts with NIRA

Conclusion: Evolocumab combined with statin therapy can significantly improve the anatomical and physiological function of the coronary arteries and downregulate the re-hospitalization rate due to UA in STEMI patients with NIRA.

Profile Image
  • Saved

Conclusions: In contemporary practice, graft failure remains common among patients undergoing CABG and is strongly associated with adverse cardiac events.

Profile Image
  • Saved
Both LDL and HDL particle concentrations associate positively with an increased risk of developing microvascular complications in patients with type 2 diabetes: lost protection by HDL (Zodiac-63) - Cardiovascular Diabetology

Both LDL and HDL particle concentrations associate positively with an increased risk of developing microvascular complications in patients with type 2 diabetes: lost protection by HDL (Zodiac-63) - Cardiovascular Diabetology

Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-01909-1

Background Triglyceride-rich lipoproteins (TRL) and low-density lipoproteins (LDL) are associated positively whereas high-density lipoproteins (HDL) are associated inversely with the development of new-onset type 2 diabetes (T2D). Here we studied...

Conclusions: Total lipoprotein particle concentrations of both LDL and HDL associate positively with an increased risk of developing microvascular complications in T2D. We propose that the protective role of HDL on the development of microvascular complications may be lost in established T2D.

Profile Image